Imagine the heart as a pump that needs to scoop blood to move it forward. In heart failure, this scooping motion stops working. This device acts like a mechanical helper that mimics that natural movement, pushing the heart's valve to keep blood flowing without needing open-heart surgery.
Patients with advanced heart failure suffer from impaired mitral plane movement, meaning the heart cannot pump enough blood to meet metabolic needs. Current solutions often require invasive surgery or have high complication rates due to skin-protruding elements.
A fully implantable cardiac support system consisting of a mitral anchor ring and a drive unit in the lower apex region. It includes a wireless recharging and monitoring system.
If you are a cardiac implant specialist dealing with the limitations of current heart failure pumps — this project developed a device that restores natural mitral plane movement. It provides a fully implantable, wireless solution that avoids skin-protruding elements.
If you are a surgery center dealing with high-risk heart failure patients — this project developed a minimally invasive implant. It allows for long-term cardiac support by synchronizing with the heart's own movements.
If you are a venture capital firm dealing with the search for high-impact cardiovascular tech — this project developed a system with a completed animal data set demonstrating proof of concept. It targets the advanced heart failure market.
Based on available project data, there is no specific unit price or manufacturing cost mentioned; however, the project received an EU contribution of EUR 2,500,000.
No. The company ceased operations in July 2023 before reaching human clinical trials, although animal proof-of-concept data was completed by June 2023.
Based on available project data, the technology was developed by Syntach AB, but the company has ceased operations, leaving the current status of the IP licenses unclear.
The project completed a comprehensive animal data set for proof of concept by June 2023, but failed to secure funding for first-in-human studies.
The system is recharged and monitored wirelessly, ensuring no elements protrude through the skin.
The consortium consisted of a single partner, Syntach AB, a Swedish SME. This 100% industry-led structure meant the project was entirely dependent on the company's ability to raise private capital to complement the EUR 2,500,000 EU grant, which ultimately led to the company's closure when funding for human trials was not secured.
Syntach AB (Note: Company ceased operations July 6, 2023)
Contact us to explore the acquisition of distressed medical IP from closed EIC projects.
